Differences between vascular and plaque core amyloid in Alzheimer's disease.
about
beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer diseaseStructural Mechanism of the Interaction of Alzheimer Disease Aβ Fibrils with the Non-steroidal Anti-inflammatory Drug (NSAID) Sulindac SulfidePyroglutamate amyloid β (Aβ) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease.Alzheimer's disease, dementia, mild cognitive impairment and the menopause: a 'window of opportunity'?Cerebral amyloid angiopathy: emerging conceptsNeuropathology of Alzheimer's diseaseLysosomal dysfunction in the brain of a mouse model with intraneuronal accumulation of carboxyl terminal fragments of the amyloid precursor protein.Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrierCerebral amyloid angiopathy: an overview.Pathological Hallmarks, Clinical Parallels, and Value for Drug Testing in Alzheimer's Disease of the APP[V717I] London Transgenic Mouse Model.Amyloid structure: conformational diversity and consequences.Normal processing of the Alzheimer's disease amyloid beta protein precursor generates potentially amyloidogenic carboxyl-terminal derivatives.A critical analysis of postulated pathogenetic mechanisms in amyloidogenesis.Current status review: cerebral amyloid.Amyloidosis in aging and Alzheimer's diseasePyroglutamate amyloid-β (Aβ): a hatchet man in Alzheimer diseaseGenetics, lifestyle and the roles of amyloid beta and oxidative stress in Alzheimer's disease.Two distinct β-sheet structures in Italian-mutant amyloid-beta fibrils: a potential link to different clinical phenotypes.Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal agingProminent cerebral amyloid angiopathy in transgenic mice overexpressing the london mutant of human APP in neurons.Predominant deposition of amyloid-beta 42(43) in plaques in cases of Alzheimer's disease and hereditary cerebral hemorrhage associated with mutations in the amyloid precursor protein gene.Selective binding of soluble Abeta1-40 and Abeta1-42 to a subset of senile plaques.High levels of circulating beta-amyloid peptide do not cause cerebral beta-amyloidosis in transgenic mice.Conformational mimicry in Alzheimer's disease. Role of apolipoproteins in amyloidogenesis.Light chain deposition disease derived from the kappa I light chain subgroup. Biochemical characterization.Monoclonal antibodies to a synthetic peptide homologous with the first 28 amino acids of Alzheimer's disease beta-protein recognize amyloid and diverse glial and neuronal cell types in the central nervous systemDistribution of beta/A4 protein and amyloid precursor protein in hereditary cerebral hemorrhage with amyloidosis-Dutch type and Alzheimer's disease.Development of a monoclonal antibody specific for the COOH-terminal of beta-amyloid 1-42 and its immunohistochemical reactivity in Alzheimer's disease and related disordersHigh tissue content of soluble beta 1-40 is linked to cerebral amyloid angiopathy.Alpha2-macroglobulin associates with beta-amyloid peptide and prevents fibril formationTruncated Amyloid-β(11-40/42) from Alzheimer Disease Binds Cu2+ with a Femtomolar Affinity and Influences Fiber Assembly.Characterization of new polyclonal antibodies specific for 40 and 42 amino acid-long amyloid beta peptides: their use to examine the cell biology of presenilins and the immunohistochemistry of sporadic Alzheimer's disease and cerebral amyloid angiopUtility of an improved model of amyloid-beta (Aβ₁₋₄₂) toxicity in Caenorhabditis elegans for drug screening for Alzheimer's diseaseAmyloid precursor protein (APP) and beta A4 amyloid in the etiology of Alzheimer's disease: precursor-product relationships in the derangement of neuronal function.Processing of the Alzheimer's disease beta A4 amyloid protein precursor (APP).Alzheimer's disease from the perspective of the systemic and localized forms of amyloidosis.Cerebral white matter lesions - associations with Aβ isoforms and amyloid PETCessation of neoangiogenesis in Alzheimer's disease follows amyloid-beta immunizationDeposition of C-terminally truncated Aβ species Aβ37 and Aβ39 in Alzheimer's disease and transgenic mouse models.Vascular cognitive impairment: Modeling a critical neurologic disease in vitro and in vivo.
P2860
Q24564120-DE59998A-4224-44AE-AF57-E6144955E50FQ30379691-0FA92330-AEA9-49B6-A576-FF35DA7A43BEQ30512697-0B71066C-AED4-463C-8F5A-BC047AD5F59FQ30620862-51122EFD-691F-4BB6-A0C6-9A124BDA26B0Q30894798-AE430015-510E-4B2E-9088-FCA7BE58C6AEQ33526568-342B2800-4277-45BC-A727-1F0119CA5268Q33603071-322071C1-02E9-41F7-8B67-564A00DE4C77Q33928434-03242111-3DA0-490C-B628-0EB5E1E5424AQ33997782-0F4D0516-6CBC-4489-8AA7-01DB07540267Q34127547-7688CFE0-4989-4519-A54C-F32A95910CF3Q34175001-B193A89E-176B-4A91-AFF1-0803ADFE40F6Q35186129-B39A4952-1FD2-4CFF-A4A3-C6AA0895434FQ35353067-7062B74C-CC1B-4F18-A779-A914AB6C5C88Q35358564-A1667577-848D-483C-9E7F-68E14F34ABE6Q35443377-3358055F-08A3-4404-9690-0F1D2CA1550FQ35604177-9F576C4F-7958-4726-A7BA-E7FEF975B4C1Q35607880-F7056006-D23E-485D-AA37-0E86386C6252Q35696876-290C58A0-89AA-4222-A36E-A855B2DE806FQ35701937-D385E377-DB8A-44DA-9E58-E1BE8D96124DQ35745836-6B0158FD-5AC5-4CC4-AA12-A0CD3F7C0C01Q35773537-B4D42E41-A52F-4FDF-8549-1878AF50E247Q35774013-A7D5FDA7-EF4C-4248-8255-578E5E149FAAQ35782286-30248A55-5258-4AB0-A9D3-68EA7C372344Q35796086-D6EE82D0-5235-4791-BB97-79EAD1C6F726Q35816605-836A1AE1-5F96-45A3-B5EC-C964986B29DAQ35816818-3CBEEBEA-2D3D-4CDF-BCFE-3AB41414EF3BQ35832849-9801CE55-478E-4CD8-B83D-0EE73DFE23ADQ35833877-F9828971-57BE-462B-A7D0-83FD02A86427Q35833986-0FE34436-7455-400F-AFCB-34686626F60BQ35985986-BCA89F11-AB61-4C9A-AE9D-784710380CC4Q36282915-C0E6888A-A06F-4427-BDA7-F9855E178919Q36438065-B32C1204-B2A2-44B4-8A5E-2C9EC061D5C1Q36460071-FB96E861-8E8B-4999-839D-BA2CFD3D1E4FQ36476991-B56765F1-D305-4842-9294-E4D6123EF968Q36477006-F57F0490-BFF1-49DF-94AB-689E41D56B54Q36477010-957D0F11-C23E-4F5D-9A90-F33DFB120041Q36559869-D0593F14-7F0B-46FA-AF5F-F8B791EC9AB8Q36644869-ED9F970B-80C9-430E-B4AD-84EC4A95B34EQ36668200-51A098F4-9D08-43F7-A18D-E3783E3D0F7FQ36767965-C2B5D828-689C-4BC3-A5C6-A504CFEBC20B
P2860
Differences between vascular and plaque core amyloid in Alzheimer's disease.
description
1988 nî lūn-bûn
@nan
1988 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1988 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
name
Differences between vascular and plaque core amyloid in Alzheimer's disease.
@ast
Differences between vascular and plaque core amyloid in Alzheimer's disease.
@en
Differences between vascular and plaque core amyloid in Alzheimer's disease.
@nl
type
label
Differences between vascular and plaque core amyloid in Alzheimer's disease.
@ast
Differences between vascular and plaque core amyloid in Alzheimer's disease.
@en
Differences between vascular and plaque core amyloid in Alzheimer's disease.
@nl
prefLabel
Differences between vascular and plaque core amyloid in Alzheimer's disease.
@ast
Differences between vascular and plaque core amyloid in Alzheimer's disease.
@en
Differences between vascular and plaque core amyloid in Alzheimer's disease.
@nl
P2093
P2860
P1476
Differences between vascular and plaque core amyloid in Alzheimer's disease.
@en
P2093
P2860
P304
P356
10.1111/J.1471-4159.1988.TB01087.X
P407
P577
1988-08-01T00:00:00Z